Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.92 USD | +10.97% |
|
+17.50% | +53.14% |
Jul. 08 | Jefferies Initiates Revolution Medicines at Buy With $63 Price Target | MT |
Jun. 20 | Revolution Medicines Insider Sold Shares Worth $446,770, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.14% | 6.53B | |
+16.71% | 44.63B | |
+42.66% | 40.46B | |
-7.92% | 38.07B | |
+33.09% | 32.27B | |
-7.10% | 27.3B | |
+14.46% | 26.53B | |
+46.73% | 14.06B | |
+34.07% | 12.54B | |
-7.61% | 11.28B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024